The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus
Abstract
Purpose: The role of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment of type 1 diabetes mellitus (T1DM), including efficacy and safety evidence, is reviewed. Summary: Currently approved treatment options for glycemic control in T1DM include insulin, which combats insulin deficiency but does not effectively target disease progression or alpha cell dysfunction; and pramlintide, whose use requires multiple daily doses and involves a high likelihood of gastrointestinal side effects. GLP-1 RAs have a unique mechanism of action in T1DM, addressing alpha cell dysfunction and thereby suppressing inappropriate glucagon secretion. GLP-1 RA dosing varies from once weekly to twice daily, and the class is well tolerated in patients with type 2 diabetes. Among the GLP-1 RAs, exenatide and liraglutide have been studied in patients with T1DM, with published evidence consistently demonstrating weight loss, decreases in total daily insulin requirements, and modest improvements in glycemic control. GLP-1 RA therapy appears to be well tolerated in patients with T1DM and is associated with nonsignificant increases in hypoglycemia risk. Conclusion: GLP-1 RA therapy represents an important add-on therapy option for achieving decreased insulin doses, weight loss, and modest improvements in HbA1c levels without significantly increasing hypoglycemia risk in patients with T1DM. Patients who have detectable C-peptide and/or are overweight or cannot achieve glycemic goals without hypoglycemia have been found to benefit the most from GLP-1 RA therapy. Further studies are warranted to evaluate these agents’ potential impact on clinical outcomes such as microvascular and macrovascular complications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Still, several studies support their use in this population, with positive effects on glycemic control and a reduction in bolus insulin doses and weight.33,34”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [33]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators (2016) · Diabetes Care · doi:10.2337/dc16-0691 · Cited by 347
Ahrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0690 · Cited by 262
Hypoglycemia in Type 1 Diabetes
McCrimmon, R. J., & Sherwin, R. S. (2010) · Diabetes · doi:10.2337/db10-0103 · Cited by 217
Dejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A. K., Holst, J. J., Tarnow, L., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00436-2 · Cited by 179
Kielgast, U., Krarup, T., Holst, J. J., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-0096 · Cited by 165
Bae, J. P., Lage, M. J., Mo, D., Nelson, D. R., & Hoogwerf, B. J. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.11.016 · Cited by 154
Rother, K. I., Spain, L. M., Wesley, R. A., Digon, B. J., Baron, A., Chen, K., Nelson, P., Dosch, H.-M., Palmer, J. P., Brooks-Worrell, B., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0773 · Cited by 133
Research works printed but not linked: 6
- 2015, Symlin (pramlintide acetate) package insert
- 2015, Byetta (exenatide) package insert
- 2017, Bydureon (exenatide extended-release) package insert
- 2017, Victoza (liraglutide) package insert
- 2017, Saxenda (liraglutide) package insert
- Marso, 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med, 375, 311, 10.1056/nejmoa1603827 · DOI · Paper page
Cited by
Alfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
“33,34 In a meta-analysis by Wang and colleagues, a combination of GLP-1 RA and insulin therapy leads to a small but signi fi cantly more signi fi cant reduction in HbA1c than traditional treat-ment ( − 0.21 [ − 0.40 to − 0.02]).”
BackgroundInfluentialMuzurović, E. M., Volčanšek, Š., Zibar, K., Janež, A., Mikhailidis, D. P., Rizzo, M., & Mantzoros, C. S. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221146371 · Cited by 123
“Exenatide and liraglutide have been studied in these patients who also have suboptimal glycemic control or obesity; consistent BW loss was demonstrated.(104) Dual agonists combining GLP1 with GIP are in the pipeline for obesity management and their potential role in T2DM.”
BackgroundHeart Rate Variability for the Early Detection of Cardiac Autonomic Dysfunction in Type 1 Diabetes
Castiglioni, P., Faini, A., Nys, A., Busser, R. D., Scherrenberg, M., Baldussu, E., Parati, G., & Dendale, P. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.937701 · Cited by 41
Lee, L., Hou, Y.-C., Hsieh, Y.-Y., Chen, Y., Shen, Y., Lee, I., Shih, M.-C. M., Hou, W., & Liu, H. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104653 · Cited by 35
Alhajahjeh, A. A., Al‐Faouri, R., Bahmad, H. F., Bader, T., Dobbs, R. W., Abdulelah, A., Abou-Kheir, W. G., Davicioni, E., Lee, D. I., & Shahait, M. (2024) · Cancers · doi:10.3390/cancers16081538 · Cited by 32
Metadata
- Authors
- Guyton, J., Jeon, M., & Brooks, A.
- Affiliations
- University of Health Sciences and Pharmacy (US)
- Corresponding author
- Brooks, Amie
- ORCID
- Jeon, Michelle
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-10-15
- Volume
- 76
- Issue
- 21
- Pages
- 1739-1748
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W2981222478
- Cited by
- 55
- References
- 22
- Citations by year
- 2026: 2 · 2025: 18 · 2024: 15 · 2023: 10 · 2022: 6 · 2021: 2 · 2020: 1 · 2019: 1
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- American Journal of Health-System Pharmacy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- GLP-1 receptor agonists, type 1 diabetes, exenatide, liraglutide, alpha-cell dysfunction, glucagon secretion, glycemic control, insulin dose reduction, weight loss, hypoglycemia risk, pramlintide, HbA1c, C-peptide
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Blood Glucose, Clinical Trials as Topic, Diabetes Mellitus, Type 1, Glucagon, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Weight Loss, Treatment Outcome, Glucagon-Secreting Cells, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. https://app.cochat.ai/papers/10.1093/ajhp/zxz179
- The paper
- Guyton, J., Jeon, M., & Brooks, A. (2019). Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxz179
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.